$226.91 2.79 (1.21%)
19:58 EDT AMGN Stock Quote Delayed 30 Minutes
Previous Close $226.91
Market Cap 150.15B
PE Ratio 72.03
Volume (Avg. Vol.) 1.82M
Day's Range 225.71 - 230.54
52-Week Range 170.56 - 244.99
Dividend & Yield 5.28 (2.33%)
AMGN Stock Predictions, Articles, and Amgen News
- From InvestorPlace
- From the Web
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
The top ten stock buybacks by S&P 500 companies in 2018 totaled $252 billion. Here are the best stocks to buy of the bunch.
CVS, Twilio, Amgen and Estee Lauder all reported earnings. Alibaba stock is breaking out. Here are our top stock trades to watch now.
Amgen reported its latest quarterly earnings results after hours today, bringing in a profit that topped expectations, yet AMGN stock fell.
The stock charts of AMGN, CTXS and GS stock are ready to start the last trading day of the week on a trade-worthy foot.
Amgen shares have a reasonable valuation, 3% dividend yield and a strong-looking chart. Is it time to buy AMGN stock now?
Given the markets’ many question marks, these safe dividend stocks to buy offer reliable yields and steady growth potential.
These ten stocks aren't exactly household names, but they each deserve a spot in a list of small-cap stocks to buy now for traders that can deal with the risk for the potential of high reward.
Amgen earnings (AMGN) were better than what analysts were calling for after hours, but AMGN stock slid as the its guidance missed the mark.
Big pharma stocks are getting good coverage from JPMorgan's healthcare event. Here are three undervalued pharmaceutical stocks to buy now.
An inverted yield curve may be around the corner, forcing investors to rethink what they really want to own.
The stock charts of AMGN, DAL and MDLZ are put under the spotlight on this week's hump-day. Here's what to watch.
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
Gilead stock is cheap selling at 11 price-earnings ratio. And it's coming into a long-term support zone. Catch the falling butter knife.
AMGN stock is still riding on a rocky road despite news of a new FDA approval. Here's what Amgen investors need to know.
These big-name stocks are showing new signs of life, making each an ideal company for your list of stocks to buy.
From Analyst Ratings
In a report released today, Stephen Byrd from Morgan Stanley maintained a Sell rating on Spire (SR – Research Report), with a price target of $70.00. The company’s shares closed last Friday at $65.89. According to TipRanks.com, Byrd is a 3-star analyst with an average return of 0.7% and a 54.2% success rate. Byrd covers
From Analyst Ratings
Credit Suisse analyst Michael Weinstein W. maintained a Sell rating on Spire (SR – Research Report) today and set a price target of $71.00. The company’s shares closed last Monday at $72.00. According to TipRanks.com, W. is a 4-star analyst with an average return of 6.5% and a 58.8% success rate. W. covers the Utilities
From The Motley Fool
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader